Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2026 Jan 31;15(1):4.
doi: 10.21037/tcr-2025-2105. Epub 2026 Jan 20.

Precision targeting of CCNE1-amplified tumors-lessons from BLU-222 and beyond

Frida Rantanen  1 , Daniela Ungureanu  1
Affiliations
Editorial

Precision targeting of CCNE1-amplified tumors-lessons from BLU-222 and beyond

Frida Rantanen et al. Transl Cancer Res. .
No abstract available

Keywords: BLU-222; CCNE1; cyclin-dependent kinase 2 inhibitor (CDK2 inhibitor); ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-2105/coif). D.U. reports that this work was supported by the Research Council of Finland (Profi6 #336449, #333583, #360437, the Sigrid Jusélius Foundation, and the Cancer Foundation Finland. The other author has no conflicts of interest to declare.

Comment on

References

    1. Yang L, Xie HJ, Li YY, et al. Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review). Oncol Rep 2022;47:82. 10.3892/or.2022.8293 - DOI - PMC - PubMed
    1. Rubinstein M, Shen S, Monk BJ, et al. Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer. Gynecol Oncol 2022;167:540-6. 10.1016/j.ygyno.2022.10.012 - DOI - PMC - PubMed
    1. Gorski JW, Ueland FR, Kolesar JM. CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer. Diagnostics (Basel) 2020;10:279. 10.3390/diagnostics10050279 - DOI - PMC - PubMed
    1. Yap TA, Elhaddad AM, Grisham RN, et al. First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer. J Clin Oncol 2023;41:3010. 10.1200/JCO.2023.41.16_suppl.3010 - DOI
    1. Dietrich C, Trub A, Ahn A, et al. INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. Cancer Discov 2024;14:446-67. 10.1158/2159-8290.CD-23-0954 - DOI - PMC - PubMed

LinkOut - more resources